Last reviewed · How we verify
Metacillin (meticillin)
Meticillin, marketed by Bristol-Myers Squibb, is an established antibiotic primarily indicated for treating bacterial septicemia, with a key composition patent expiring in 2028. Its mechanism of action, which inhibits bacterial cell wall synthesis, provides a strong therapeutic foundation against gram-positive bacteria. However, the presence of multiple off-patent competitors in the same class, including dicloxacillin, cloxacillin, oxacillin, and nafcillin, poses a significant threat to its market share.
At a glance
| Generic name | meticillin |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | meticillin |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Bacterial septicemia
- Infection of skin AND/OR subcutaneous tissue
- Sinusitis
- Staphylococcal pneumonia
Common side effects
Key clinical trials
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Linezolid Plus Standard of Care (NA)
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock (PHASE3)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (PHASE2)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metacillin CI brief — competitive landscape report
- Metacillin updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI